Page 7 - Oncocyte News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncocyte. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncocyte Today - Breaking & Trending Today

StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report released on Monday. The brokerage issued a sell rating on the stock. Other analysts have also recently issued research reports about the company. Needham & Company LLC dropped their target price on OncoCyte from $9.00 to $4.25 and set a buy […] ....

United States , Needham Company , Goldman Sachs Group Inc , Raymond James Financial Services Advisors Inc , Oncocyte Corporation , Vanguard Group Inc , Free Report , James Financial Services Advisors , Sachs Group , Get Free Report , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report released on Tuesday morning. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC dropped their target price on shares of OncoCyte from $9.00 to $4.25 and set a buy rating for the company in a […] ....

United States , Millennium Management , Oncocyte Company Profile , Geode Capital Management , Defender Capital , Oncocyte Corporation , Investment Company Inc , Vanguard Group Inc , Needham Company , Free Report , Cyte Stock Down , Capital Management , Get Free Report , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note released on Monday morning. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC decreased their price objective on shares of OncoCyte from $9.00 to $4.25 and set a buy rating on the stock in a […] ....

United States , Vanguard Group Inc , Goldman Sachs Group Inc , Millennium Management , Oncocyte Corporation , Oncocyte Company Profile , Geode Capital Management , Needham Company , Free Report , Sachs Group , Capital Management , Get Free Report , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report published on Saturday. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC lowered their price objective on OncoCyte from $9.00 to $4.25 and set a buy rating for the company in a research report on Thursday, […] ....

United States , Oncocyte Corporation , Goldman Sachs Group Inc , Raymond James Financial Services Advisors Inc , Needham Company , Vanguard Group Inc , Free Report , Cyte Stock Down , James Financial Services Advisors , Sachs Group , Get Free Report , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

Equities research analysts at StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a research note issued on Friday. The brokerage set a “sell” rating on the stock. Separately, Needham & Company LLC lowered their price objective on shares of OncoCyte from $9.00 to $4.25 and set a “buy” rating for […] ....

United States , Needham Company , Cubist Systematic Strategies , Oncocyte Corporation , Raymond James Financial Services Advisors Inc , Balyasny Asset Management , Get Free Report , Cyte Stock Down , James Financial Services Advisors , Systematic Strategies , Asset Management , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,